Cagrilintide & CagriSema: The Amylin+GLP-1 Combo Redefining Weight Loss (2026 Guide)

Cagrilintide & CagriSema: The Amylin+GLP-1 Combo Redefining Weight Loss (2026 Guide)

For years, GLP-1 receptor agonists like semaglutide and tirzepatide dominated the conversation around obesity medicine. But a new class of combination therapy is forcing experts to rethink what's possible in weight loss pharmacology. CagriSema — a once-weekly co-formulation of cagrilintide and semaglutide — pairs a GLP-1 agonist with an amylin analogue to attack appetite from two independent neurological pathways simultaneously. The Phase 3 REDEFINE trial data, published in the New England Journal of Medicine in 2025, showed over 20% average body weight reduction in people without type 2 diabetes — results that have reshaped how clinicians and patients think about next-generation obesity treatment.

This guide covers everything you need to know: what amylin is, how cagrilintide works, what the clinical trials actually showed, how CagriSema stacks up against the competition, and when this drug could reach pharmacy shelves.

What Is Amylin — and Why Has It Been Overlooked?

To understand cagrilintide, you first need to understand amylin. Amylin (also called islet amyloid polypeptide, or IAPP) is a peptide hormone co-secreted by the pancreatic beta cells alongside insulin in response to meals. It plays a critical supporting role in glucose regulation and appetite control that, until recently, was largely underappreciated.

Amylin's primary functions include slowing gastric emptying (food stays in the stomach longer, reducing the speed of glucose absorption and sustaining feelings of fullness), suppressing glucagon (blunting the post-meal glucagon surge that drives glucose elevations in type 2 diabetes), signaling satiety in the brain (amylin acts on the area postrema and nucleus tractus solitarius, brain regions that regulate food intake and body weight), and reducing caloric intake by creating a sense of fullness even before large quantities of food are consumed.

Here's the problem: people with obesity and type 2 diabetes often have significantly reduced amylin secretion. This creates a vicious cycle — impaired satiety signals, faster gastric emptying, and stronger hunger responses all conspire to make weight loss harder even when someone is trying to eat less.

The first approved amylin analogue, pramlintide (Symlin), demonstrated these effects but required multiple daily injections and had modest weight loss outcomes. What was needed was a long-acting version — one that could be dosed once weekly alongside a GLP-1 agonist. That's exactly what cagrilintide is.

What Is Cagrilintide? How Does It Work?

Cagrilintide is a fatty-acid-acylated, long-acting analogue of human amylin developed by Novo Nordisk. The acylation modification — similar to the technology used in semaglutide and insulin degludec — dramatically extends its half-life, enabling once-weekly subcutaneous dosing.

Receptor Mechanism

Cagrilintide is a non-selective agonist at amylin receptors 1, 2, and 3 (AMY1R, AMY2R, AMY3R), which are formed by calcitonin receptor (CTR) dimerization with receptor activity-modifying proteins (RAMPs 1–3). Research published in eBioMedicine (2025) confirmed that cagrilintide's weight-lowering effects depend primarily on AMY1R and AMY3R signaling in the brain — particularly in hypothalamic and brainstem areas that regulate energy homeostasis.

Unlike GLP-1 receptor agonists, which primarily work through the vagus nerve and central GLP-1R signaling, amylin receptor activation engages different neural circuits. This mechanistic distinction is the core rationale for combining the two: they work together through complementary and partially non-overlapping pathways, producing greater appetite suppression and weight loss than either agent achieves alone.

Why Combine With Semaglutide?

Early phase 2 data confirmed the synergy hypothesis. When cagrilintide (1.2 mg and 2.4 mg) was added to semaglutide, participants achieved 15.7% and 17.1% weight loss at 20 weeks, respectively — compared to just 9.8% with semaglutide plus placebo. This roughly 5–7 percentage point boost in weight loss at an early timepoint was striking enough to greenlight a full Phase 3 program.

The REDEFINE Trials: What the Phase 3 Data Shows

Novo Nordisk ran two pivotal Phase 3 trials under the REDEFINE name, both published in the New England Journal of Medicine in June 2025.

REDEFINE 1 (Without Type 2 Diabetes)

REDEFINE 1 enrolled adults with BMI ≥30 kg/m² (or ≥27 with an obesity-related complication), without type 2 diabetes. In this randomized, double-blind trial, participants received once-weekly CagriSema 2.4/2.4 mg, semaglutide alone, cagrilintide alone, or placebo for 68 weeks alongside lifestyle intervention.

The results were striking: –20.4% mean body weight reduction with CagriSema versus –3.0% with placebo. Sixty percent of participants on CagriSema lost ≥20% of body weight, and 23% lost ≥30%. Weight loss was significantly greater with CagriSema than with either drug alone.

REDEFINE 2 (With Type 2 Diabetes)

REDEFINE 2 enrolled adults with BMI ≥27 kg/m² and type 2 diabetes (HbA1c 7–10%), randomized 3:1 to CagriSema 2.4/2.4 mg or placebo for 68 weeks. Mean body weight reduction was –13.7% with CagriSema vs. –3.4% with placebo. Remarkably, 73.5% of CagriSema participants achieved HbA1c ≤6.5% vs. only 15.9% with placebo, demonstrating a dual benefit for both obesity and glycemic control.

Side Effects and Safety Profile

CagriSema's side effect profile largely mirrors what clinicians expect from semaglutide, with gastrointestinal (GI) events being the most common concern.

In REDEFINE 1, 79.6% of CagriSema participants experienced GI adverse events (vs. 39.9% with placebo). The most common were nausea, vomiting, diarrhea, constipation, and abdominal pain. The majority were transient and mild-to-moderate in severity, most prominent during dose escalation.

Heart rate increases (a known effect of amylin receptor signaling) were observed and warrant monitoring in patients with underlying cardiovascular conditions. Injection site reactions occurred but were generally mild. The combination did not raise safety signals beyond what would be expected from each component.

The GI tolerability profile is meaningfully higher than semaglutide alone — a tradeoff patients and clinicians will need to weigh against the enhanced weight loss benefit.

CagriSema vs. Tirzepatide vs. Retatrutide: How Do the Numbers Stack Up?

Here's an honest comparison based on current trial data:

Semaglutide 2.4 mg (Wegovy) — GLP-1 agonist — ~15% Phase 3 weight loss — FDA approved.
Tirzepatide 15 mg (Zepbound) — GLP-1 + GIP dual agonist — ~22.5% — FDA approved.
CagriSema 2.4/2.4 mg — GLP-1 + amylin — ~20.4% — NDA filed December 2025.
Retatrutide 12 mg — GLP-1 + GIP + glucagon triple agonist — ~28.7% — Phase 3 ongoing.

CagriSema vs. Tirzepatide: The Head-to-Head Reality

In February 2026, results from the REDEFINE 4 trial — a direct head-to-head comparison of CagriSema 2.4/2.4 mg versus tirzepatide 15 mg — delivered an uncomfortable verdict for Novo Nordisk: CagriSema failed to demonstrate non-inferiority to tirzepatide.

Under the treatment regimen estimand, patients on CagriSema lost 20.2% vs. 23.6% on tirzepatide. Even under the efficacy estimand, CagriSema achieved 23.0% vs. tirzepatide's 25.5%. The difference was statistically significant and prevented CagriSema from claiming equivalence — but 20–23% weight loss remains extraordinary by any historical benchmark.

CagriSema vs. Retatrutide: Looking Ahead

Retatrutide, Eli Lilly's triple agonist (GLP-1/GIP/glucagon), achieved a remarkable 28.7% average weight loss at 68 weeks in Phase 3. It won't reach FDA submission until late 2026 and approval until 2027 at the earliest, but when it does, it will represent the most potent pharmacological option in obesity medicine.

FDA Approval Timeline and Availability

On December 18, 2025, Novo Nordisk submitted a New Drug Application (NDA) for CagriSema to the FDA — making it the first once-weekly combination of a GLP-1 agonist and an amylin analogue ever submitted for regulatory review.

As of April 2026, the NDA is under standard FDA review. With a typical 10–12 month review period, an approval decision is expected in Q4 2026 or Q1 2027. Even with approval in late 2026, commercial availability is realistically mid-2027 after manufacturing scale-up.

What About Compounding?

No legal pathway to compounded cagrilintide exists in 2026. Cagrilintide is not FDA-approved and has not been placed on the FDA's 503A or 503B bulk drug substance lists. Compounding pharmacies cannot legally prepare it for patient use outside of investigational protocols. The only legitimate access in 2026 is enrollment in one of Novo Nordisk's ongoing clinical trials.

What CagriSema Means for Obesity Medicine

CagriSema represents something genuinely new in obesity pharmacology — not just a more potent version of existing drugs, but a different mechanistic approach entirely. Adding amylin receptor activation opens a complementary satiety circuit to those targeted by GLP-1 agonists.

For patients who plateau on semaglutide, the amylin mechanism could provide additional benefit. For type 2 diabetes management, the REDEFINE 2 data showing 73.5% of participants achieving HbA1c ≤6.5% is extraordinary. And for the field broadly, CagriSema's arrival means clinicians will soon have approved options across multiple distinct mechanistic classes — enabling increasingly personalized obesity treatment.

The Bottom Line

Cagrilintide and CagriSema are supported by rigorous Phase 3 data showing meaningful weight loss that surpasses GLP-1 monotherapy. The amylin mechanism brings genuine novelty to obesity medicine.

That said, the head-to-head data against tirzepatide tempers unrealistic expectations. CagriSema is not the most potent weight loss drug in development, and it carries a higher GI side effect burden. For patients seeking strong efficacy with a novel mechanism who can tolerate the GI effects, it will be a compelling option once approved. Watch for the FDA's response to the CagriSema NDA in late 2026 — it will be one of the most consequential regulatory decisions in metabolic medicine in years.